Literature DB >> 19668174

Beyond the biotech IPO: a brave new world.

Bruce L Booth1.   

Abstract

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model.

Mesh：

Year:  2009        PMID： 19668174     DOI： 10.1038/nbt0809-705

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  1 in total

1.  Pharmas partner in venture seeking drug discovery tools.

Authors:  George S Mack
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908
  1 in total
  9 in total

1.  What does the current biotech stock market value?

Authors:  Laura McNamee; Fred Ledley
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  Is it virtuous to be virtual? The VC viewpoint.

Authors:  Justin Chakma; Jeff L Calcagno; Ali Behbahani; Shawn Mojtahedian
Journal:  Nat Biotechnol       Date:  2009-10       Impact factor: 54.908

3.  In defense of life sciences venture investing.

Authors:  Bruce L Booth; Bijan Salehizadeh
Journal:  Nat Biotechnol       Date:  2011-07-11       Impact factor: 54.908

4.  Why universities should step up in venture investing.

Authors:  Amanda Christini
Journal:  Nat Biotechnol       Date:  2012-10       Impact factor: 54.908

5.  The changing face of corporate venturing in biotechnology.

Authors:  Georg von Krogh; Boris Battistini; Fotini Pachidou; Pius Baschera
Journal:  Nat Biotechnol       Date:  2012-10       Impact factor: 54.908

Review 6.  Regenerative medicine: then and now--an update of recent history into future possibilities.

Authors:  E Polykandriotis; L M Popescu; R E Horch
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

7.  Translational science by public biotechnology companies in the IPO "class of 2000": the impact of technological maturity.

Authors:  Laura McNamee; Fred Ledley
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

8.  Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.

Authors:  Ekaterina Galkina Cleary; Laura M McNamee; Skyler de Boer; Jeremy Holden; Liam Fitzgerald; Fred D Ledley
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

9.  'If I had a hedge fund, I would cure diabetes': endogenous mechanisms for creating public goods.

Authors:  John Liechty; Stefan Wuyts
Journal:  SN Bus Econ       Date:  2021-09-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.